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stina.therese.sollid@unn.noAbstractObjective: To determine the relationship between serum total 25-hydroxyvitamin D (25(OH)D), directly measured free 25(OH)
D and calculated free 25(OH)D with regard to vitamin D-binding protein (DBP) phenotypes, sex, BMI, age and season, and
their interrelationship to vitamin D supplementation.
Design, patients and interventions: A randomized controlled trial with 20 000 IU of vitamin D3 per week or placebo for
12 months was designed. A total of 472 subjects, 236 in each of the intervention groups, were included in the analyses.
Main outcome measures: Baseline serum concentrations and increases in serum total 25(OH)D, directly measured free
25(OH)D, calculated free 25(OH)D and DBP.
Results: Serum total 25(OH)D and DBP concentrations were significantly lower in subjects with the phenotype Gc2/Gc2
compared to phenotypes with the Gc1S allele, and lower in males compared to females. When using directly measured free
25(OH)D, the differences related to DBP phenotypes and sexes were clearly diminished. All calculated free 25(OH)D
concentrations were overestimated compared to the directly measured free 25(OH)D. Serum parathyroid hormone showed
an inverse correlation with all vitamin D parameters analyzed. The increases after 12 months of vitamin D supplementation
were not significantly different for any of the vitamin D parameters regardless of DBP phenotype, sex or age.
Supplementation with vitamin D did not affect serum DBP.
Conclusion: Direct measurements of free 25(OH)D reduce the differences seen in total 25(OH)D between DBP phenotype
groups and sexes, probably caused by differences in DBP concentrations. With conditions affecting serum DBP
concentrations, direct measurements of free 25(OH)D should be considered.ice
.0 UEuropean Journal of
Endocrinology
(2016) 174, 445–452IntroductionTotal 25-hydroxyvitamin D (25(OH)D) is the metabolite
used to evaluate a person’s vitamin D status. In the
circulation close to 90% of total 25(OH)D are bound to
vitamin D-binding protein (DBP) with high affinity, about
10% are more loosely bound to albumin and !0.1% arein an unbound, or free, form (1). For the calculation of free
25(OH)D one therefore needs to know serum total
25(OH)D concentrations as well as serum DBP and
albumin concentrations (2). Recently it has also been
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174 :4 446commercially available kit. According to the ‘free hor-
mone hypothesis’ it is the unbound hormone that is
the biologically active; for 25(OH)D this may also include
the fraction bound to albumin that together with
the unbound form have been classified as ‘bio-available’
25(OH)D (3).
DBP is synthesized by the liver, a process that is
stimulated by estrogen (4). Some conditions, such as
cirrhosis due to affected synthesis (5) and nephritic
syndrome due to protein loss (4) are associated with low
DBP concentrations, while pregnancy (6) and estrogen
therapy (7) are both known to cause higher DBP
concentrations. More than 120 genetic variations of DBP
exist; however, for practical purposes the three major
polymorphic alleles of DBP in humans, GC1F, GC1S and
GC2, yielding six allelic combinations and corresponding
phenotypes, are the relevant ones (8). These genetic
factors have been showed to explain almost 80% of the
variations in serum DBP concentrations, which show great
differences between ethnic groups (9). Thus, in Europeans
the Gc1S allele is most frequently seen, whereas in
Africans GC1F is the most common allele (4).
In spite of lower serum total 25(OH)D concentrations
African Americans have better bone health and less
fractures than European Americans (10). However, Powe
et al. (9) have shown that the known differences in serum
total 25(OH)D between African and European Americans
equalizes when evaluating calculated free or bio-available
25(OH)D concentrations, and differences in serum total
25(OH)D may therefore not reflect differences in biologi-
cal activity. Recently this finding in African and European
Americans was confirmed by Aloia et al. (11) using directly
measured free serum 25(OH)D. Accordingly, other
differences in serum total 25(OH)D, like those between
DBP phenotypes, sexes, age groups, BMI categories, as well
as seasons, may diminish or disappear when evaluating
free 25(OH)D concentrations. On the other hand,
relations with presumed vitamin D related effects, like
parathyroid hormone (PTH) secretion, might increase.
Furthermore, there are conflicting reports on the DBP
response to vitamin D supplementation (12, 13). If a
response exists, that would affect not only the total
25(OH)D, but to an even greater degree the free
25(OH)D concentrations. We have recently performed a
large randomized controlled trial (RCT) with high dose
vitamin D supplementation where we have genotyped
for DBP polymorphisms, have calculated and directly
measured concentrations of free serum 25(OH)D, and
therefore had the opportunity to address the above
questions.www.eje-online.orgSubjects and methods
Overall design
The data in the present study (baseline and 12 months)
were obtained from an RCT where vitamin D vs placebo
was given to subjects with prediabetes for 5 years with
prevention of diabetes as primary endpoint. Included in
the analysis are those with complete datasets for serum
albumin, serum total 25(OH)D, serum directly measured
free 25(OH)D and serum DBP.
Study population
Methods regarding the conduct of the RCT have been
published in detail previously (14). Briefly, inclusion criteria
were 21–80 years of age and impaired fasting glucose (IFG)
and/or impaired glucose tolerance (IGT). Exclusion criteria
were primary hyperparathyroidism, sarcoidosis or other
granulomatous disorders, urolithiasis, cancer during the
last 5 years, reduced kidney function, or unstable angina
pectoris, acute myocardial infarction or stroke the last year.
Fertile women had to use contraception, could not be
pregnant, and could not be lactating. Study participants
were allowed to take vitamin D supplements of maximum
400 IU/day. At baseline 511 subjects received study medi-
cation, 256 subjects were given 20 000 IU of vitamin D3 per
week and 255 placebo. Four hundred eighty-four, 242
in each group, completed the 1-year visit.Measurements
Height and weight were measured wearing light clothing and
no shoes. BMI was calculated as weight (kg) divided by
squared height (m2). Serum calcium, serum PTH and HbA1c
were measured as previously described (15). Serum total
25(OH)D was measured by an in-house LC–MS/MS, the limit
of detection (LoD) was !4 mmol/l, and the between day
coefficient of variation (CV) !9% (16). Serum albumin was
measured by a colorimetric method (bromocresol green)
using an automated analyzer, Cobas 8000 (c702, Roche
Diagnostics). Serum DBP was measured by using an in house
competitive RIA with a polyclonal antibody according to
Kauppinen-Mäkelin et al. (17) at the Hormone Laboratory,
Oslo University Hospital. Direct measurement of serum free
25(OH)D was done using a competitive ELISA kits from
Diasource Diagnostics based on patented MAB developed by
Future Diagnostics (http://www.vitamin-d-diagnostics.com/
Vitamin-D/Free-25OH-Vitamin-D/Free-25OH-Vitamin-D-
ELISA-96-tests-RUO), the range was 0.2–87.4 pmol/l, the LoD
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bio-available 25(OH)D
Genotyping was performed by KBiosciences (http://www.
lgcgenomics.com/genotyping/) with a competitive allele-
specific PCR (KASPar) assay. Based on genotyping for two
single-nucleotide polymorphisms (SNPs) in the DBP gene
(rs7041 and rs4588), the six phenotypes were identified
(Supplementary Tables 1 and 2, see section on supple-
mentary data given at the end of this article). For serum
25(OH)D the binding coefficient for albumin is 6!105/M
and the binding coefficient for DBP is 7!108/M (2). Free- and
bio-available serum 25(OH)D concentrations were calculated
using serum total 25(OH)D, DBP and albumin concen-
trations using a free testosterone equation (18) adapted for
calculating free 25(OH)D (19) (Supplementary material).Statistical analysis
Normal distribution was evaluated by visual inspection of
histograms and by skewness and kurtosis. Normally
distributed data are presented as meanGS.D., PTH being
the only non-normally distributed variable is presented as
median (2.5th and 97.5th percentiles). Level of signi-
ficance was set at P!0.05 (two-tailed). Independent
samples t-test was used to compare the vitamin-D and
placebo groups, whereas paired samples t-tests were used
to compare serum calculated free 25(OH)D and directly
measured free 25(OH)D. For sex c2 test and for age and
BMI one-way ANOVA were used to determine differences
in distribution between DBP phenotype groups, BMI
groups and age groups. A general linear model was used







Serum PTH (pmol/l) 5
Serum albumin (g/l)
Serum DBP (mmol/l)
Serum total 25(OH)D (nmol/l)
Serum calculated free 25(OH)D (pmol/l)
Serum calculated bio-available 25(OH)D (nmol/l)
Serum directly measured free 25(OH)D (pmol/l)
PTH, parathyroid hormone; DBP, vitamin D binding protein; 25(OH)D, 25-hydroassociations with sex, BMI, age and season as covariates.
The Bonferroni procedure was used for post-hoc analysis.
Independent sample t-tests were used to evaluate
differences between sex and season, whereas linear trend
analyses were used across BMI groups and age groups.
Univariate correlations were assessed with Pearson corre-
lation coefficient (PTH was log transformed). IBM SPSS
Statistics version 22 was used for all statistical analyses.Ethics
The study was approved by the Norwegian Medicines
Agency and by the Regional Committee for Medical
Research Ethics. The trial is registered at ClinicalTrials.gov
(NCT00685594).Results
Participant characteristics
Complete data sets were available in 472 subjects, 236
in each of the intervention groups. Baseline values are
presented in Table 1. The directly measured free 25(OH)D
concentrations were lower than the calculated free
25(OH)D (Table 1). There were no significant differences
between the vitamin D and placebo groups.Serum total 25(OH)D, calculated free 25(OH)D, calculated
bio-available 25(OH)D, directly measured free 25(OH)D
and DBP in relation to DBP phenotypes at baseline
As expected, Gc1S was by far the most abundant allele.
There were no significant differences between the DBP



















Table 2 Distribution of sex, age, BMI, albumin, DBP and vitamin D parameters according to DBP phenotype. General linear model
with sex, BMI, age and season as covariates. Bonferroni method for post-hoc analysis.
DBP phenotypes
Gc1S/Gc1S Gc1S/Gc1F Gc1S/Gc2 Gc1F/Gc1F Gc1F/Gc2 Gc2/Gc2
Number of subjects 148 124 117 20 39 24
Sex (females/males) 58/90 53/71 37/80 7/13 16/23 8/16
BMI (kg/m2) 29.3G4.5 30.2G4.2 30.4G4.2 31.3G4.0 29.7G4.6 30.1G2.9
Age (years) 62.2G8.4 61.3G9.2 62.4G8.4 63.3G8.9 61.3G9.0 62.4G9.3
PTH (pmol/l) 5.6 (5.2, 5.9) 6.0 (5.5, 6.4) 5.9 (5.4, 6.3) 5.3 (4.6, 5.9) 5.4 (5.0, 5.7) 5.2 (4.5, 5.8)
Serum albumin (g/l) 45.1G2.3 45.3G2.0 45.1G2.5 45.5G2.0 45.4G2.2 45.4G2.5
Serum DBP (mmol/l) 3.7G0.5b 3.8G0.5b 3.6G0.5b 3.9G0.7b 3.8G0.7 b 3.1G0.4 a
Serum total 25(OH)D (nmol/l) 62.9G23.9b 64.2G22.9b 59.6G19.6d 56.8G17.0 56.9G17.7 43.9G13.5 a,c
Serum calculated free 25(OH)D (pmol/l) 21.0G7.4 21.1G6.9 20.4G6.8 18.6G6.4 18.8G6.2 17.3G5.5
Serum calculated bio-available 25(OH)D (nmol/l) 8.6G3.1 8.7G2.8 8.3G2.7 7.7G2.7 7.7G2.6 7.1G2.2
Serum directly measured free 25(OH)D (pmol/l) 13.4G4.2 14.2G4.3 13.9G4.2 12.4G3.3 14.0G4.6 12.2G4.1
DBP, vitamin D binding protein; 25(OH)D, 25-hydroxyvitamin D.
aSignificantly lower than P!0.001.
bP!0.001.
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ficantly lower for the phenotype Gc2/Gc2 compared to
Gc1S/Gc1S, Gc1S/Gc1F and GC1S/Gc2 (Table 2). The
phenotype Gc2/Gc2 also had significantly lower serum
DBP concentration compared with all the other pheno-
type groups (Table 2).
For calculated free 25(OH)D, calculated bio-available
25(OH)D and directly measured free 25(OH)D the
differences between the DBP phenotypes diminished and
were no longer statistically significant (Table 2). The least
differences between phenotypes were found for the direct
measurements; as an example the difference between
Gc2/Gc2 and Gc1S/Gc1S were 30.2% for total 25(OH)D,
17.6% for calculated free 25(OH)D and only 9.0% for
directly measured free 25(OH)D.
We also calculated free 25(OH)D using specific
binding coefficients for the six different DBP phenotypes;
however, this did not improve the results (data not
shown).Serum total 25(OH)D, calculated free 25(OH)D,
calculated bio-available 25(OH)D, directly measured
free 25(OH)D and DBP in relation to sex, BMI, age and
season at baseline
Males had significantly lower serum total 25(OH)D than
females, a difference of 10.5% (Supplementary Table 3, see
section on supplementary data given at the end of this
article). Similarly, serum DBP concentrations were signi-
ficantly lower for males compared to females; and in linewww.eje-online.orgwith this no significant differences were found for serum
calculated free 25(OH)D, calculated bio-available
25(OH)D or directly measured free 25(OH)D concen-
trations (Supplementary Table 3).
With increasing BMI a non-significant trend (PZ0.08)
for decreasing serum total 25(OH)D was seen with a 9.2%
difference between the lowest and highest BMI groups. A
similar, but significant trend was seen for serum DBP. As
for total 25(OH)D there were no significant differences in
the free and bio-available 25(OH)D concentrations
between BMI groups; further, for the directly measured
free 25(OH)D the difference had almost completely
disappeared (Supplementary Table 3).
There was with increasing age a significant linear trend
with increasingly higher serum total 25(OH)D, calculated
free 25(OH)D, calculated bio-available 25(OH)D and
directly measured free 25(OH)D (Supplementary Table 3).
However, no such trend was seen for serum DBP, and
therefore the differences between the lowest and highest
age groups for total 25(OH)D and the corresponding
differences for directly measured free 25(OH)D were
basically the same (17.0% and 17.1% respectively).
For season we compared the three consecutive highest
months of serum total 25(OH)D (July–September) with the
three lowest (February–April), and since their serum DBP
did not differ significantly, the difference remained
statistically significant, and also almost identical, for the
calculated free 25(OH)D, calculated bio-available
25(OH)D and directly measured free 25(OH)D (P!0.001)
(data not shown).











Serum total 25(OH)D (nmol/l) 1 0.73* 0.24* K0.04 K0.15*
Serum directly measured free 25(OH)D
(pmol/l)
0.73* 1 0.05 K0.05 K0.12*
Serum DBP (mmol/l) 0.24* 0.05 1 0.15* K0.04
Serum albumin (g/l) K0.04 K0.05 0.15* 1 K0.06†
Serum PTH (pmol/l)a K0.21* K0.17* K0.05 K0.09 1
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free 25(OH)D, directly measured free 25(OH)D,
albumin, DBP and PTH at baseline
Serum PTH was negatively and similarly correlated with
serum total 25(OH)D and directly measured free 25(OH)D
(Table 3). Additionally, strong correlations were found
between serum total 25(OH)D and directly measured free
25(OH)D (Table 3), and also between all other vitamin D
parameters (data not shown). Serum DBP correlated with
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Figure 1
Correlation between delta (12 month values minus baseline value)
serum total 25(OH)D and delta directly measured free 25(OH)D.Effect of vitamin D supplementation on serum DBP,
total 25(OH)D, calculated free 25(OH)D and directly
measured free 25(OH)D
In both the vitamin D and the placebo group there was a
slight and similar non-significant decrease in serum DBP
after 1 year (K0.2G0.5 and K0.2G0.6 mmol/l respectively).
Similarly, there were no statistically significant differences
between the six DBP phenotypes, sexes, BMI groups or age
groups regarding change in serum DBP (Supplementary
Tables 4 and 5, see section on supplementary data given at
the end of this article). Further, there were no significant
differences between DBP phenotypes, sexes or age groups in
changes in serum total 25(OH)D, calculated free 25(OH)D or
directly measured free 25(OH)D (Supplementary Tables 4
and 5). Even so, there appeared to be non-significant
differences in the increase in serum total 25(OH)D between
DBP groups phenotype (Supplementary Table 4). For all
25(OH)D measures the highest increases were seen for
subjects in the lowest BMI groups (Supplementary Table 5).
There was a strong correlation between increase in all
measures of serum 25(OH)D as exemplified between delta
serum total 25(OH)D and delta serum directly measured
free 25(OH)D in Fig. 1. The correlation was similar for all
six DBP phenotypes (data not shown).Discussion
In the present study we have found that serum total
25(OH)D concentrations are dependent on DBP pheno-
type, that differences between DBP phenotypes diminish
when calculating or measuring serum free 25(OH)D, and
that serum DBP concentrations are unaffected by vitamin
D supplementation. Further, calculations appear to over-
estimate the free 25(OH)D concentrations compared to
the direct measurements.
Serum total 25(OH)D concentrations were signi-
ficantly lower for the DBP phenotype Gc2/Gc2 compared
to phenotypes with the Gc1S allele as previously reported
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free 25(OH)D also were lowest in this phenotype, the
differences were greatly diminished and no longer
significant. Thus, the difference between the DBP pheno-
types Gc2/Gc2 and Gc1S/Gc1S decreased from 30.2% for
total 25(OH)D to 9.0% for directly measured free
25(OH)D. This is in line with the almost identical free
25(OH)D concentrations in black and white Americans
(9, 11), despite great differences in total 25(OH)D, due to
different distribution of DBP phenotypes (4). This could
also partly explain why African Americans have better
bone health than European Americans despite lower total
25(OH)D concentrations.
It is well known that serum DBP concentrations
are affected by phenotype (21), and in our study serum
DBP concentrations for the phenotype Gc2/Gc2 were
significantly lower compared to all other phenotypes.
This has also been found in most (20, 22, 23), but not
all previous studies (9). Thus, Powe et al. (9) found that
the DBP phenotype Gc1F/Gc1F, predominantly found
in black Americans, had by far the lowest serum DBP
concentration. This is contrary to our study, and
other studies from Scandinavia (21, 22), where this
phenotype had the highest serum DBP concentration. As
reported by Bouillon et al. the discrepancy may be due to
differences in antibodies used in the DBP assays (24), or
perhaps it reflects that there are other race-related factors
than DBP phenotype that affect the serum DBP
concentration.
Males had significantly lower serum total 25(OH)D
concentrations and also serum DBP concentrations than
females. For calculated free 25(OH)D and calculated bio-
available 25(OH)D these differences between the sexes
diminished, and for the directly measured free 25(OH)D
the concentrations were equal. The difference in serum
DBP between sexes has previously been reported (25) and
is most likely caused by the estrogen susceptible DBP
synthesis (4). Similar, although non-significant, the
difference between the lowest and highest BMI group for
serum total 25(OH)D concentrations were reduced for the
directly measured free 25(OH)D, probably because of the
significant linear trend with lower serum DBP concen-
tration with higher BMI. For BMI earlier reports are
conflicting with some reporting differences in serum DBP
(26), while others report no differences (25, 27). This
question is therefore not settled.
As in previous reports from our region (28, 29),
there was for age groups a significant linear trend with
the highest serum total 25(OH)D concentrations in the
oldest subjects. This is most likely due to a diet richerwww.eje-online.orgin fatty fish and a higher use of vitamin D supplements
in the oldest age groups (28). However, serum DBP did
not differ between age groups, and a significant positive
linear trend was also seen for all the other 25(OH)D
measures.
Similar to that seen for age group, there were no
differences in serum DBP between the months with the
highest and lowest serum total 25(OH)D concentrations,
and accordingly, the differences between these months
remained for serum calculated free 25(OH)D, calculated bio-
available 25(OH)D and directly measured free 25(OH)D.
We found that the calculated serum free 25(OH)D
concentrations are overestimated compared to the directly
measured free 25(OH)D. For calculations of serum free
25(OH)D concentration DBP concentrations are needed.
Since different DBP assays recognize the DBP phenotypes
differently (11, 24), this will affect the calculated free
25(OH)D concentrations. Furthermore, the validity of the
equation for calculating free 25(OH)D concentration
which is derived from an equation for free testosterone
(2), has been questioned (24). Therefore, it may be wise
not to use the calculated concentrations before these
issues have been settled.
We also performed analyses with the DBP phenotype
specific binding coefficients. However, and contrary to
what we expected, this did not improve the results. The
binding coefficients for Gc1S, Gc1F and GC2 are the
binding coefficients for the homozygote DBP phenotypes;
however, the binding coefficients used for the hetero-
zygote DBP phenotypes were the mean of the two
combined haplotypes binding coefficient (30). These
binding coefficients may not be correct, which may at
least partly explain our unexpected findings.
Since vitamin D both indirectly, through increased
calcium absorption from the intestines, and directly,
through inhibition of PTH synthesis, decreases the PTH
secretion, the serum PTH concentrations has been
suggested as a vitamin D biomarker (31). One could
therefore hypothesize that the 25(OH)D measure that best
correlate with the serum PTH concentrations would be the
best indicator of the vitamin D status. Unfortunately,
previous studies are conflicting; Schwartz et al. (32)
reported a significant inverse correlation with PTH for
directly measured free 25(OH)D, but not for calculated free
25(OH)D, whereas Aloia et al. (11) in one study reported a
significant negative correlation with PTH for total
25(OH)D, but not for directly measured free 25(OH)D.
However, in another study by Aloia et al. (33) a
significantly negative correlation for both total 25(OH)D
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correlation with PTH. Although the free hormone
hypothesis is appealing, it should be recalled that there
is a receptor-mediated endocytosis of the DBP/total
25(OH)D complex in the proximal renal cells (34), and
probably also in other cells (1), which could favor serum
total 25(OH)D as an indicator of vitamin D status.
As compared to placebo, there was no effect on the
serum DBP concentrations by vitamin D supplementation
for 1 year regardless of DBP phenotype, sex, BMI or age
group which is similar to that reported by Ponda et al. (13)
and Sonderman et al. (35). Similarly, in the vitamin D group
there were no significant differences in increase for any of
the vitamin D parameters between the DBP phenotypes,
sexes or age groups. On the other hand, there appear to be
non-significant differences between the DBP phenotype
groups regarding the increase in serum total 25(OH)D;
however, the DBP phenotype groups are small and thereby
limits the power to detect any real differences. It therefore
appears unlikely that the DBP concentration is regulated in
order to keep the free fraction of serum 25(OH)D stable as
seen in other endocrine systems (36).
There are some limitations to our study; we included
subjects with prediabetes which limits the generalizability
of the results, the study population consists almost
exclusively of Caucasians leaving us with a skewed
distribution of DBP phenotypes, and we did not have
bone density measurements that could have given
additional information regarding which 25(OH)D par-
ameter is the best biomarker of vitamin D status. On the
other hand, we included a large number of subjects, had
direct measurements of serum free 25(OH)D, and could
also examine the effects of vitamin D supplementation on
different vitamin D parameters and serum DBP, which
so far have not been thoroughly studied.
In conclusion, we have found that the direct
measurement of free 25(OH)D diminishes differences
between DBP phenotypes and sexes as compared to
serum total 25(OH)D. In situations where DBP phenotypes
differ between groups, as seen between white and black
Americans, and in conditions associated with low DBP
concentrations like liver cirrhosis or nephritic syndrome,
or high DBP concentrations like pregnancy and estrogen
therapy, direct measurement of serum free 25(OH)D
should be considered.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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